NK Cell Fusion Protein Anticancer Treatment Composition
Summary
The European Patent Office published EP4067481A1, a patent application for a composition comprising NK cells and a fusion protein combining IL-2 protein and CD80 protein for anticancer treatment. Applicants GI Cell, Inc. and GI Innovation, Inc. seek exclusive IP rights covering the composition, methods of preparation, and therapeutic use across 38 designated European states.
What changed
EPO published patent application EP4067481A1 covering NK cell compositions engineered with IL-2/CD80 fusion proteins for anticancer applications. The filing claims methods for preparing the immunotherapeutic composition, pharmaceutical formulations, and therapeutic use in treating cancers, particularly hematologic malignancies and solid tumors.
For biotechnology and pharmaceutical companies developing cell-based immunotherapies, this patent establishes priority rights for GI Cell and GI Innovation in the European market. Competitors must consider freedom-to-operate implications when developing similar NK cell-based products or IL-2/CD80 fusion approaches. The patent's broad claim scope across 38 designated contracting states creates significant IP barriers for rival formulations.
What to do next
- Monitor for patent grant confirmation
- Review freedom-to-operate for cell-based cancer therapies
- Assess licensing opportunities for NK cell immunotherapies
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR ANTICANCER TREATMENT, COMPRISING NK CELLS AND FUSION PROTEIN WHICH COMPRISES IL-2 PROTEIN AND CD80 PROTEIN
Publication EP4067481A1 Kind: A1 Apr 01, 2026
Applicants
GI Cell, Inc., GI Innovation, Inc.
Inventors
JANG, Myoung Ho, HONG, Chun-Pyo, YANG, Zung Yoon, KOH, Young Jun, LEE, June Sub, CHOI, Young Joo
IPC Classifications
C12N 5/0783 20100101AFI20231208BHEP C12N 15/63 20060101ALI20231208BHEP C07K 14/55 20060101ALI20231208BHEP C07K 14/705 20060101ALI20231208BHEP A61K 35/17 20150101ALI20231208BHEP A61P 35/00 20060101ALI20231208BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.